Meet Herantis Pharma at BIO-Europe 2023 in Munich, Germany

Herantis Pharma Plc (“Herantis”), a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease, announce today that CEO, Antti Vuolanto and CSO, Henri Huttunen will attend the BIO-Europe partnering conference, from November 6th to 8th in Munich, Germany.

We look forward to connecting with business executives and investors in the pharma and biotech community to discuss the very positive data from our Phase 1a clinical trial:

• HER-096 Phase 1a clinical trial met primary and secondary endpoints;
• Subcutaneous single dose injections of HER-096 had overall good safety and tolerability profile in young and older healthy subjects;
• The pharmacokinetic profile showed fast uptake of HER-096 after subcutaneous injection and demonstrated blood-brain barrier (BBB) penetration in humans.

About Bio-Europe 2023:
BIO-Europe is Europe's largest partnering conference serving the global biotechnology industry. The 29th annual BIO-Europe will take place November 6–8, 2023 in Munich, Germany, and it will convene over 5,000 life science professionals representing more than 2,220 companies from over 60 countries. Attendees will take part in 27,000 one-to-one meetings over the course of the event.

For more information, please contact:
Julie Silber/Gabriela Urquilla
Tel: +46 (0)7 93 486 277/+46 (0)72-396 72 19
Email: [email protected]

Certified Advisor: UB Securities Ltd, Finland: +358 9 25 380 225

About Herantis Pharma Plc
Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. Herantis’ lead product HER-096, is an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein. It combines the compelling mechanism of action of CDNF with the convenience of subcutaneous administration. The Phase 1a clinical trial demonstrated a good safety and tolerability profile, and efficient blood-brain barrier penetration of subcutaneously administered HER-096 in humans. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland.

Company website: www.herantis.com